Board of Directors

Chairman of the Board since 2021

Catharina Bäärnhielm, PhD, born 1952

Ulf is a trained pharmacist with over 35 years of experience from the pharmaceutical industry. Ulf has been active in research, development and marketing of both pharmaceuticals and diagnostics with many years of experience in handling industrial collaborations, financial issues and contacts with regulatory authorities in both Europe and the United States. Among previous positions, the position as CEO of the oncology company Aprea and OxyPharma are noticeable. Ulf has previously held a number of senior positions within Pharmacia. Ulf currently works as a consultant and is currently chairman of the board of Lipum AB and a board member of TikoMed AB and MedicaNatumin AB.

Holding in the Company: 0 shares

Independence: Ulf is independent in relation to the Company and the Company’s largest owner

Founder and Board member since 2015

Kjell Olmarker, PhD, born 1958

With over 100 publications in the area of chronic back pain Kjell is a well renowned researcher within the area. He holds a professorship at Gothenburg University and works actively in the development of STA363 and has conducted a majority of the company’s in vivo studies and is supporting the board in scientific matters.

Holding in the Company: 500 000 shares

Independence: Kjell is dependent in relation to the Company and the Company’s largest owner

Board member since 2018

Jane Buus Laursen, PhD, born 1975

Jane Buus Laursen is Corporate Vice President and head of Novo Nordisk’s Late Stage & Commercial Business Development. Before that, she spent 15 years at AstraZeneca where she completed a large number of deals with biotechs, pharma and academia spanning from early stage to late stage business transactions across all of AstraZeneca’s strategic areas. Her CV includes licensing deals, M&As, commercial partnerships and divestments of late stage clinical and on-market assets, in addition to spin-out of early stage assets.

Holding in the Company: 0 shares

Independence: Jane is independent in relation to the Company and the Company’s largest owner

Board member since 2021

GUDRUN ANSTRÉN, born 1955

Gudrun is a trained pharmacist with over 35 years of experience from marketing companies in the pharmaceutical industry in global positions, including Organon, ICI-Pharma, Zeneca and AstraZeneca, as well as consulting in smaller biotech companies. Gudrun has been active in all aspects of drug development, which has included the management of a number of global projects from pre-clinic to phase-3. She has worked in the approval phase as well as during launch and in several different disease areas.

Holding in the Company: 0 shares

Independence: Gudrun is independent in relation to the Company and the Company’s largest owner

Board member since 2020

Erik Kinnman, PhD, MD, born 1958

Erik Kinnman has broad leadership experience and expertise from various assignments in the life science sector and many years of experience from leading positions in pharmaceutical companies such as AstraZeneca and Sobi. Erik’s expertise and experience encompass clinical development, business strategy, business development and investor relations, and he also has experience from the finance sector. He holds an Executive MBA degree from Stockholm School of Economics and extensive research qualifications from the Karolinska Institute where he received his PhD degree and Associate Professorship. Erik holds an MD degree with specialist expertise in neurology and pain relief. He is also the Managing Director of Abliva AB.

Holding in the Company: 15 462 shares

Independence: Erik is independent in relation to the Company and the Company’s largest owner

Board member since 2021

GUNNAR FERNSTRÖM, born 1950

Gunnar is Investment Director at InnovationsKapital, a venture capital company focusing on innovative companies in the early stages from the Nordic region. Gunnar is responsible for their investments in Health / Medical and Life Sciences and has made a total of 18 investments in the area. He is currently a member of the boards of Besedo, PBM, Scienta Scientific and Chalmers Innovation and chairman of Chalmers Industriteknik. Gunnar has a degree in chemical engineering from Chalmers.

Holding in the Company: 0 shares

Independence: Gunnar is independent in relation to the Company and the Company’s largest owner